Effect of Testosterone Level on Mortality in Patients With Left Ventricular Assist Device

Basit Öğe Kaydı
dc.contributor.authorSimsek, Evrim
dc.contributor.authorKilic, Salih
dc.contributor.authorKemal, Hatice Soner
dc.contributor.authorNalbantgil, Sanem
dc.contributor.authorOzturk, Pelin
dc.contributor.authorYildirim, Ilgin
dc.contributor.authorOzbaran, Mustafa
dc.date.accessioned2020-12-01T12:05:59Z
dc.date.available2020-12-01T12:05:59Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground and objectives. Testosterone deficiency is associated with mortality in patients with heart failure; however, its effects on patients undergoing Left Ventricular Assist Device (LVAD) implantation are unclear. We investigated the role of total testosterone (TT) and free testosterone (FT) levels on mortality undergoing LVAD implantation. Methods. Between December 2010 and December 2014, 101 consecutive male patients who underwent LVAD implantation and had plasma testosterone measurement (TT and FT) in the last month before operation were included in the study. Demographics, follow-up, and mortality data were analyzed retrospectively. Results. the mean age of the patients was 51.7 +/- 11 years. TT and FT levels were in the below normal range of 31.6% (n = 32) and 65.3% (n = 66) of the patients, respectively. the mean follow-up time was 355 +/- 268 days, and 32 (31%) patients died during follow-up. Cumulative survival rates were significantly worse in patients with low TT and FT than patients in the normal range (P <.001 and P =.029, respectively). Multivariate analysis after adjustment for clinical variables, age, albumin, C-reactive protein, total cholesterol, chronic kidney disease, diabetes mellitus (DM), and leukocytosis showed that low TT and FT were independently associated with poor survival (HR, 3.680; 95% CI, 1.615-8.385 P =.002 and HR, 3.816; 95% CI, 1.279-11.383, P =.016, respectively). Conclusion. Low TT and FT levels were independent risk factors for mortality in patients with LVAD.en_US
dc.identifier.doi10.1016/j.transproceed.2019.07.028en_US
dc.identifier.endpage3423en_US
dc.identifier.issn0041-1345
dc.identifier.issn1873-2623
dc.identifier.issue10en_US
dc.identifier.pmid31733796en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage3418en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2019.07.028
dc.identifier.urihttps://hdl.handle.net/11454/63129
dc.identifier.volume51en_US
dc.identifier.wosWOS:000504951000038en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleEffect of Testosterone Level on Mortality in Patients With Left Ventricular Assist Deviceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu